Thakur Vikram, Ratho Radha Kanta, Panda Jiban Jyoti
Department of Virology, Post Graduate Institute of Medical Education and Research, PGIMER, Sector-12, Chandigarh, 160012 India.
Chemical Biology Unit, Nanotherapeutics Lab, Institute of Nano Science and Technology, (INST), Phase-10, Sector-64, Mohali, Punjab 160062 India.
Virusdisease. 2021 Mar;32(1):131-136. doi: 10.1007/s13337-021-00679-2. Epub 2021 Mar 17.
Coronavirus disease 19 (COVID-19) is the prime global health concern of the year 2020. Infecting more than 112 million individuals so far, this pandemic has already reported more than 2.4 million deaths around the world. With such high infectivity and mortality, effective treatment intervention is the need of the hour. The integration of medical science with nanotechnology may solve the current problem by exploring collective benefits. In this manuscript, we theoretically proposed the duo-combination of an approved antiviral i.e. favipiravir along with an immunomodulator i.e. tocilizumab loaded in protein-lipid nanovesicles as an effective anti-COVID-19 therapeutic. This proposed nanomedicine delivered through the respiratory mode may enhance the effectiveness of the antiviral and help in restricting the virus and associated complications, utilizing both anti-viral activity and immunomodulation in COVID-19 patients. This proposed nanomedicine could be an effective treatment modality for the severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2) infected patients.
2019冠状病毒病（COVID-19）是2020年全球主要的健康关注点。截至目前，这场大流行已感染超过1.12亿人，全球报告的死亡人数已超过240万。鉴于如此高的传染性和死亡率，当下急需有效的治疗干预措施。医学与纳米技术的结合或许能通过探索其共同益处来解决当前问题。在本手稿中，我们从理论上提出将一种已获批的抗病毒药物即法匹拉韦与一种免疫调节剂即托珠单抗组合，负载于蛋白质-脂质纳米囊泡中，作为一种有效的抗COVID-19治疗方法。这种通过呼吸道给药的纳米药物可能会增强抗病毒效果，并有助于在COVID-19患者中利用抗病毒活性和免疫调节作用来限制病毒及相关并发症。这种纳米药物可能是治疗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者的一种有效治疗方式。
